Date Rape Drugs / Club Drugs - Complete Clinical Guide

Sources: Rosen's Emergency Medicine 10e, Kaplan & Sadock's Synopsis of Psychiatry, Maudsley Prescribing Guidelines 15e, Lippincott Illustrated Reviews: Pharmacology, Stahl's Essential Psychopharmacology, Tintinalli's Emergency Medicine, Forensic Medicine & Toxicology 36e (2026), Kaplan-Sadock Synopsis

INTRODUCTION AND OVERVIEW

DRUG 1: GHB (Gamma-Hydroxybutyrate)

Introduction

Street Names

• Liquid Ecstasy, Liquid X, Liquid G
• GBH (Grievous Bodily Harm)
• Georgia Home Boy
• Fantasy, Easy Lay, Scoop
• Goop, Cherry Meth, Organic Quaalude

Mechanism of Action

1. A full agonist at specific GHB receptors (dedicated receptors in the brain)
2. A partial agonist at GABA-B receptors - acting as an antagonist when GABA is high and an agonist when GABA is low

Physical Appearance and How It Is Used/Abused

• Usually a clear, colorless liquid with a slightly salty taste; also available as white powder or capsules
• Virtually odorless and tasteless in beverages - ideal for surreptitious drugging
• Administered orally (swallowed directly or mixed into drinks)
• Onset: 15-30 minutes after ingestion
• Duration: effects last up to 6 hours
• Ingestion of 1 g produces euphoria and relaxation
• Ingestion of 2 g produces deep sleep
• Ingestion of 4 g produces coma - particularly when mixed with alcohol (synergistic effect)
• Also misused by bodybuilders for its anabolic properties

Intoxication / Clinical Features

• Dose-dependent sedation ranging from euphoria → disinhibition → sedation → coma
• Anterograde amnesia (critical for date rape use)
• Dizziness, confusion, disorientation
• Slurred speech, ataxia
• Hallucinations (at higher doses)

• Bradycardia
• Hypotension

• Respiratory depression (potentially life-threatening)
• Apnea

• Nausea, vomiting
• Myoclonic jerks (can resemble seizures)
• Hypotonia
• Hypothermia
• Diaphoresis

Dependence

Withdrawal Syndrome

• Onset: 1-6 hours after last dose (very rapid, due to GHB's short half-life of ~30-60 minutes)
• Autonomic instability: tachycardia, hypertension, diaphoresis, fever
• Neurological: tremors, agitation, confusion, delirium, psychosis
• Seizures (can be severe)
• Insomnia (often profound)
• Course can resemble alcohol withdrawal delirium (delirium tremens)
• Can persist 5-15 days, longer than alcohol withdrawal

Acute Treatment of Intoxication

• Primarily supportive - no specific antidote exists
• Airway management and respiratory support (intubation if needed)
• IV access, cardiac monitoring, pulse oximetry
• Position in recovery position to prevent aspiration
• Exclude co-ingestants (especially opioids, alcohol, other CNS depressants)
• Exclude traumatic injuries
• Flumazenil and naloxone are not effective
• Most patients recover spontaneously within 2-6 hours

Treatment of Withdrawal (Maudsley Guidelines 15e)

• Use CIWA-Ar (Clinical Institute Withdrawal Assessment) to monitor severity
• Diazepam loading in severe cases
• Baclofen 10 mg PO TDS added as adjunctive pharmacotherapy where benzodiazepines prove inadequate (baclofen acts at GABA-B receptors, similar to GHB's partial agonism)
• Phenobarbital has been used for severe GHB withdrawal (case series, 2023)
• Pharmaceutical-grade GHB tapering (in Netherlands/Belgium protocol): more physiological, reduces seizure risk - matched-subject observational study showed non-inferiority to BZD tapering (Beurmanjer et al., CNS Drugs 2020)

• Dijkstra et al: Detoxification with titration and tapering in GHB-dependent patients - Dutch GHB monitor project. Drug Alcohol Depend 2017; 170:164-173
• Freeman et al: Phenobarbital to manage severe GHB withdrawal: a case series. Drug Alcohol Rev 2023; 42:27-32

Dependence Treatment / Long-Term

• No established pharmacotherapy for GHB use disorder
• Cognitive behavioral therapy and motivational enhancement
• Baclofen has been investigated as maintenance therapy (GABA-B agonist)
• Monitoring for co-occurring stimulant use disorder (GHB is frequently co-used with methamphetamine in chemsex contexts)

DRUG 2: FLUNITRAZEPAM (Rohypnol)

Introduction

Street Names

• Roofies, Roche, Rope
• La Roche, Rib, Forget-Me Pill
• Mexican Valium, Mind Eraser
• Wolfies, Circles

Mechanism of Action

• Sedation and hypnosis
• Anterograde amnesia (the key factor in date rape)
• Muscle relaxation
• Anxiolysis
• Anticonvulsant effects

Physical Appearance and How It Is Used/Abused

• Originally: white tablet, odorless and tasteless when dissolved
• Current formulation (after regulation): Light green pill with blue core - turns beverages blue when dissolved, to aid detection. However, generic versions may not contain the blue dye.
• Tablets sold on street for $0.50-$5 each
• Most tablets in North America produced illegally in Mexico/Latin America
• Packaged in foil-backed clear plastic blister packs
• Ingested orally; commonly used with alcohol (potentiates effects dramatically)
• Also snorted, and occasionally injected
• Used by cocaine abusers to moderate the "comedown" from stimulants

Intoxication / Clinical Features

• Disinhibition (similar to alcohol but more pronounced)
• Profound sedation, confusion, disorientation
• Anterograde amnesia (hallmark - complete blackout)
• Slurred speech, impaired coordination
• Hypotonia, muscle relaxation
• Loss of consciousness at higher doses
• Respiratory depression
• Paradoxical agitation possible
• Despite marked CNS depression, patients can usually be aroused with noxious stimuli

Dependence and Withdrawal

• Dependence develops with repeated use (days to weeks)
• Tolerance develops across all effects
• Withdrawal can be life-threatening - similar to alcohol withdrawal

• Anxiety, agitation, insomnia
• Tremors, sweating
• Tachycardia, hypertension
• Seizures (potentially fatal)
• Psychosis, delirium
• Timeline: onset 24-72 hours after last dose, can last 1-2 weeks

Acute Treatment of Intoxication

• Supportive care: airway protection, respiratory monitoring
• Flumazenil (benzodiazepine antagonist) - use with caution: risk of precipitating seizures in chronic users; very short duration compared to flunitrazepam's long half-life requires prolonged monitoring for recurrent sedation
• Monitor for hypoxia, hypoventilation, aspiration
• Not detected on routine urine drug screens - specific testing (police crime lab) needed; metabolites detectable up to 72 hours in urine with specialized testing

Treatment of Withdrawal

• 3-5 day inpatient detoxification with 24-hour intensive medical monitoring
• Long-acting benzodiazepine (diazepam) substitution and tapering
• Phenobarbital as alternative for severe cases or BZD cross-tolerance issues
• Seizure precautions throughout
• CIWA-Ar monitoring protocol

Dependence Treatment

• Standard substance use disorder treatment for benzodiazepine dependence
• Gradual taper over weeks to months
• CBT for anxiety/insomnia management
• Address underlying co-occurring substance use (often polydrug users)

DRUG 3: KETAMINE

Introduction

Street Names

• Special K, Vitamin K
• Kit Kat, Cat Valium
• Super K, Jet, Purple
• Super Acid, Bump

Mechanism of Action

• Dissociative anesthesia - state of analgesia + sedation + amnesia with eyes-open
• Preservation of airway reflexes (at anesthetic doses)
• Sympathomimetic cardiovascular effects (tachycardia, hypertension)
• Hallucinogenic and psychedelic effects at sub-anesthetic doses

• Opioid receptor interactions
• Sigma receptor activity
• Dopaminergic and serotonergic modulation
• Activation of AMPA receptor signaling (relevant to antidepressant effect)

Physical Appearance and How It Is Used/Abused

• Commercially available as a clear liquid or off-white powder (after evaporation)
• Odorless, tasteless - can be added to drinks undetected
• Routes of abuse: intranasal ("bumps"), oral, intramuscular injection, vaporized and inhaled
• At clubs: typically snorted as powder
• Duration of action: 30-60 minutes IM; 15-30 minutes intranasal
• The "K-hole": very high doses produce a profound dissociative state with complete detachment from reality, near-death-experience feeling - sought by some users

Intoxication / Clinical Features

• Dissociation, derealization, depersonalization
• Euphoria, dreamlike state
• Perceptual distortions, visual/auditory hallucinations
• Altered sense of time
• Analgesia
• Mild tachycardia and hypertension (sympathomimetic)
• Nystagmus (characteristic)
• Ataxia, impaired coordination

• Profound dissociation, immobility
• Complete amnesia of the experience
• Respiratory depression possible (though airway reflexes usually preserved)
• Emergence reactions - agitation, confusion on awakening

• Ketamine cystitis: severe, progressive lower urinary tract symptoms (frequency, urgency, dysuria, hematuria), upper tract damage (hydronephrosis), potentially requiring cystectomy
• Cognitive impairment, memory deficits
• Hepatic/biliary damage (cholangiopathy)
• Psychological dependence

Dependence and Withdrawal

• Psychological dependence is well established with regular use
• Physical dependence with withdrawal syndrome can occur with heavy use
• Withdrawal features: craving, anxiety, restlessness, diaphoresis, shaking - generally less severe than GHB or benzodiazepine withdrawal

Acute Treatment of Intoxication

• Primarily supportive - most effects short-lived
• Quiet, low-stimulation environment (reduce "emergence reactions")
• Benzodiazepines for agitation (diazepam 5-10 mg IV/IM)
• Cardiac monitoring (tachycardia/hypertension)
• Airway monitoring
• Avoid physostigmine (worsens emergence reactions)
• Benzodiazepines preferred over antipsychotics for acute agitation

Dependence Treatment

• No approved pharmacotherapy
• CBT, relapse prevention
• Urological follow-up mandatory (ketamine cystitis monitoring - renal ultrasound, cystoscopy)
• Complete abstinence often required to prevent further urological damage
• Hepatology input if biliary involvement

DRUG 4: MDMA (Methylenedioxymethamphetamine / Ecstasy)

Introduction

Street Names

• Ecstasy, E, X, XTC
• Molly (purportedly "pure" MDMA powder)
• Adam, Beans, Roll
• Disco Biscuits, Hug Drug
• Love Drug, Clarity

Mechanism of Action

1. Massively increases serotonin release from presynaptic terminals into the synaptic cleft
2. Blocks serotonin reuptake transporter (SERT) - preventing reuptake
3. Inhibits serotonin synthesis - depleting intracellular stores acutely
4. Also releases norepinephrine and dopamine
5. Sometimes described as an "empathogen" due to unique serotonin-mediated emotional effects

Physical Appearance and How It Is Used/Abused

• Colorful tablets/pills with logos (e.g., dove, mitsubishi, smiley face) - often sold as "ecstasy"
• "Molly" = crystalline powder or capsules (marketed as "purer")
• WARNING: MDMA products are frequently adulterated with methamphetamine, ketamine, methylone (synthetic cathinone), or PMA/PMMA (much more dangerous)
• Ingested orally; sometimes insufflated or dissolved in liquid
• Typical recreational dose: 75-125 mg
• Widely used at raves, clubs, music festivals; enhances music, dancing, social bonding

Intoxication / Clinical Features

• Euphoria and emotional closeness/empathy ("entactogenic")
• Heightened sensory perception - music, touch especially pleasurable
• Increased energy, sociability, sense of well-being
• Mild hallucinations and perceptual distortions
• Increased heart rate and blood pressure

• Hyperthermia - potentially life-threatening (most dangerous acute effect, especially in hot/crowded environments with dancing)
• Tachycardia, hypertension
• Diaphoresis, dehydration
• Bruxism and trismus (jaw clenching/teeth grinding) - characteristic
• Dry mouth
• Nausea
• Mydriasis
• Hyponatremia - SIADH-like syndrome from excessive water intake + ADH hypersecretion; can cause cerebral edema (more common in females)
• Serotonin syndrome - with concomitant use of serotonergic drugs (SSRIs, MAOIs); features: hyperthermia + clonus + altered mental status
• Rhabdomyolysis (from hyperthermia + excessive motor activity)
• Cardiac dysrhythmias
• Seizures (at high doses or hyperthermia)

Dependence

• MDMA produces primarily psychological dependence rather than physical dependence
• Tolerance develops rapidly with repeated use (rapidly diminishing effects)
• Post-MDMA "comedown" / withdrawal:
  • Occurs 1-2 days after use (consistent with serotonin depletion)
  • Depression, fatigue, irritability, poor concentration ("mid-week blues")
  • Insomnia
  • Anxiety, reduced sociability
  • More severe depression, irritability, and unsociability than alcohol withdrawal (study data)
  • Duration typically 1-5 days

Neurotoxicity

• Repeated MDMA use causes selective, long-lasting damage to serotonergic nerve terminals (demonstrated in animals)
• In humans: associated with cognitive deficits, memory impairment (potentially permanent with heavy use)
• Metabolized (in part) to MDA, which has greater neurotoxic potential

Acute Treatment of Intoxication

1. Temperature management is the top priority - hyperthermia is the main killer
   • Move to cool environment
   • Tepid water misting, ice packs
   • Aggressive cooling measures
2. Benzodiazepines (IV diazepam/lorazepam) - reduce agitation, help with cooling, control seizures
3. Life-threatening hyperthermia: neuromuscular blockers + endotracheal intubation to control excessive movement and heat generation
4. Cyproheptadine (serotonin antagonist) for serotonin syndrome - note: only available orally, limits use in severe cases
5. Correct hyponatremia carefully (hypertonic saline if severe/symptomatic; avoid overrapid correction)
6. Cardiac monitoring
7. Rhabdomyolysis: IV fluids, urine alkalinization
8. Do NOT give extra water to hyperthermic patients without checking sodium first (risk of worsening hyponatremia)

Treatment of Withdrawal / Dependence

• No approved pharmacotherapy for MDMA use disorder
• Supportive care for the comedown period
• Short-term sleep aids if needed (non-BZD, avoid dependence)
• SSRIs: theoretically might help serotonin depletion but clinical evidence limited
• CBT for relapse prevention
• Neuropsychological monitoring for long-term cognitive effects

DRUG 5: METHAMPHETAMINE (as Club Drug)

Introduction

Mechanism

Intoxication Features

• Euphoria, increased energy, decreased appetite
• Tachycardia, hypertension, hyperthermia
• Diaphoresis, flushing, mydriasis
• Bruxism, skin picking ("tweaking"), formication
• Tooth decay ("meth mouth") from dry mouth + bruxism + poor hygiene
• Paranoia, psychosis (hallucinations, persecutory delusions)

Methamphetamine Psychosis

• Psychotic symptoms in ~25% of users persist 1 month after use
• Between 16-38% of patients initially diagnosed with methamphetamine psychosis are later diagnosed with schizophrenia
• Indistinguishable from primary psychotic disorder when persistent
• Treatment: Benzodiazepines for acute agitation; olanzapine or aripiprazole if antipsychotics needed. Note: fourfold increased risk of EPSEs in methamphetamine users. - Maudsley Guidelines 15e

Withdrawal

• Low mood, listlessness, fatigue, irritability, hypersomnia
• Intense craving
• Generally not life-threatening (unlike GHB/BZD)

Treatment

• Mirtazapine: 2022 systematic review and meta-analysis showed reduction in methamphetamine consumption in meth use disorder
• CBT (most evidence-based psychosocial intervention)
• Contingency management
• No approved pharmacotherapy in US/EU

DRUG 6: LSD (Lysergic Acid Diethylamide)

Introduction

Street Names

• Acid, Blotter, Tabs
• Trips, Dots, Lucy

Mechanism

Clinical Features

• Visual hallucinations and perceptual distortions (dose-dependent)
• Synesthesia (cross-sensory experiences)
• Emotional lability, paranoia at high doses
• Panic reactions ("bad trips")
• Effects last 8-12 hours
• No physiological dependence
• Tolerance develops rapidly (requires escalating doses)
• Flashbacks (HPPD - Hallucinogen Persisting Perception Disorder): occur up to 1 year after use

Acute Treatment

• Quiet, low-stimulation "talk-down" environment
• Benzodiazepines for severe agitation or panic
• Antipsychotics (haloperidol) for extreme cases
• No specific antidote

DRUG 7: CHLORAL HYDRATE ("Mickey Finn")

Introduction

Mechanism

Clinical Features

• CNS and respiratory depression
• Cardiovascular toxicity (hallmark): sensitizes myocardium to catecholamines; ventricular tachycardia/fibrillation, torsades de pointes, atrial fibrillation
• GI irritation (esophagitis, hemorrhagic gastritis)
• Citrus/pear-like odor to breath
• Toxic dose: ~10 g in adults; potentially fatal cardiac dysrhythmia

Treatment

• Supportive: airway management
• Dysrhythmias: short-acting beta-blocker (propranolol/esmolol) - NOT epinephrine (sensitized myocardium)
• Avoid naloxone
• Hemodialysis for severe toxicity (trichloroethanol is dialyzable)

SUMMARY TABLE: CLINICAL COMPARISON

DETECTION AND FORENSIC ASPECTS

• GHB, flunitrazepam, and ketamine are not detected on routine ED toxicology screening (Tintinalli's Emergency Medicine)
• GHB has a very short half-life (~30-60 min) - urine/serum must be collected within 4-8 hours of suspected ingestion
• Flunitrazepam metabolites detectable in urine up to 72 hours with specialized testing
• MDMA may appear on amphetamine screens but false negatives occur
• Urine sample preservation crucial: refrigerate at 4°C, freeze if >72 hours
• In suspected drug-facilitated sexual assault: contact police crime laboratory for specialized testing
• Hair analysis (hair strands) can detect drugs weeks to months later - increasingly used in forensic cases

RECENT ADVANCES (2023-2026)

1. GHB withdrawal - pharmaceutical GHB tapering: A matched-subject observational study (Belgium/Netherlands, published in CNS Drugs 2020, ongoing real-world use post-2022) showed pharmaceutical GHB tapering is non-inferior to benzodiazepine tapering for GHB-dependent patients, with potentially fewer complications. The Dutch GHB Monitor Project continues to refine protocols. (Maudsley Guidelines 15e reference: Beurmanjer H et al.)
2. Phenobarbital for severe GHB withdrawal: A 2023 case series (Freeman et al., Drug Alcohol Rev 2023) documented successful use of phenobarbital for managing severe GHB withdrawal refractory to benzodiazepines - adding an important option to the armamentarium.
3. MDMA-assisted psychotherapy: MDMA was under late-stage clinical trials for PTSD (Phase 3 MAPS trials). The FDA issued a Complete Response Letter in August 2024 citing concerns about trial design - not yet approved, but ongoing research continues. Promising signals in combat veterans and sexual assault survivors.
4. Esketamine (Spravato): The S-enantiomer of ketamine, approved by FDA (2019) for treatment-resistant depression and major depression with acute suicidal ideation. Administered intranasally under supervised clinical settings. Creates new considerations around ketamine's medical vs. illicit use.
5. New designer drugs / novel psychoactive substances (NPS): Bath salts (synthetic cathinones like MDPV, mephedrone, methylone) continue to emerge as club drugs. MDPV (methylenedioxypyrovalerone) is a particularly potent synthetic stimulant. Forensic medicine 36e (2026) highlights detection challenges for NPS.
6. Medetomidine contamination (2026): A 2026 review (Annals of Emergency Medicine) documented emergence of medetomidine (a veterinary alpha-2 agonist) in the illicit drug supply - implications for emergency care and withdrawal management, representing a new threat.
7. Drug checking services: Harm reduction programs now offer real-time drug testing at festivals/venues (e.g., fentanyl test strips, reagent kits, mass spectrometry). Evidence supports reduction in high-risk drug use when people know what substances are present.
8. Liquid GHB testing strips: Development of colorimetric point-of-care GHB test strips for drinks has advanced - though sensitivity/specificity remains imperfect.

KEY POINTS FOR CLINICAL PRACTICE

1. Assume co-ingestion - most date rape scenarios involve multiple drugs plus alcohol
2. GHB and flunitrazepam are invisible on routine drug screens - clinical suspicion must drive management
3. GHB withdrawal can kill - recognize it, treat aggressively with high-dose benzodiazepines ± baclofen
4. MDMA hyperthermia is the leading cause of death - aggressive cooling is the priority
5. Ketamine cystitis is an underrecognized serious complication of chronic use
6. Forensic evidence collection is time-critical: collect blood and urine immediately in suspected sexual assault; contact specialist labs
7. Psychological trauma from drug-facilitated assault is profound - forensic exam + psychological support + legal referral are all part of care
8. Adulteration is rampant - "Molly" or "ecstasy" bought on the street may contain fentanyl, methamphetamine, PMMA, or synthetic cathinones that are far more dangerous